Healthcare

Syntara said on 10 November 2026 that it had halted new enrolment in the Phase 1b trial of SNT-9465, a topical panlysyl oxidase inhibitor. The decision followed an internal review of local tolerability findings from the blinded study population.

Starpharma completed manufacture of the non-radiolabelled clinical material for its lead radiopharmaceutical, DEP HER2-Lu, and submitted a Clinical Trial Application in Europe. The company is preparing for a first-in-human Phase 1 study.

During the quarter the company progressed its US regulatory pathway after the FDA granted its request for a pre-IND Type B meeting on the proposed development program for VB0004 in idiopathic pulmonary fibrosis.

Syntara shares were down 28.95% at $0.014 during the session. On 10 November 2026, the same day as the trading session, the company announced it had paused recruitment in the Phase 1b study of its topical SNT-9465 for hypertrophic sternotomy scars, after reports of …

Global Health shares were down 10.00% at $0.045 during the session. Its Appendix 4C and quarterly report, released on 26 October 2026, showed operating cash outflow of $828,000 for the September quarter, an improvement of $237,000 on the prior year quarter.

• The company said it met its FY26 underlying EBITDA guidance.

• For the year to 30 June 2026, announced on 27 August 2026, Sigma reported normalisedRevenueof $10.8 billion, up 15.5% on pro forma FY25 of $9.4 billion.